 SYDNEY, Australia, Sept. 21, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce it will report final Overall Survival OS data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha efti or IMP321 in metastatic breast cancer at the Society for Immunotherapy of Cancer SITC Annual Meeting 2021. SITC 2021 is taking place in Washington, US and virtually from 10-14 November. 